ADELAIDE, Australia / RankWire.AI / – Researchers in Australia have pinpointed a molecular switch that influences the progression of aggressive tumors, unveiling a potential new route for therapies aimed at preventing secondary cancers. The study, published in EMBO Molecular Medicine, involves scientists from Adelaide University and the Olivia Newton-John Cancer Research Institute. They demonstrated that re-establishing the function of a crucial regulatory molecule called miR-342 leads to a significant decrease in tumor metastasis. Their results offer a promising new approach for combating triple-negative breast cancer by targeting dormant cancer cells before they develop into life-threatening lesions in distant organs.
Although triple-negative breast cancer makes up 10% to 15% of the roughly 21,000 breast cancer cases diagnosed annually in Australia, it accounts for a disproportionate share of mortality. This subtype lacks estrogen, progesterone, and HER2 receptors, which renders standard hormone-targeted treatments ineffective. The researchers revealed that when miR-342 levels drop, a cancer-promoting pathway called E2F becomes hyperactive, enabling dormant cancer cells to disseminate and establish dangerous secondary tumors throughout the body.
New Targeted Treatments Offer Hope for Preventing High-Risk Metastasis
Pre-clinical models showed that restoring miR-342 levels dramatically reduced the spread of cancer cells to distant organs. Additionally, the team discovered that palbociclib, an existing CDK4/6 inhibitor drug approved for hormone receptor-positive breast cancers, significantly impeded metastatic tumor growth in models with low miR-342 expression. These findings suggest that assessing miR-342 levels could enable clinicians to repurpose current therapeutics for patients at high risk of metastasis.
Associate Professor Philip Gregory, co-senior author from Adelaide University’s Centre for Cancer Biology, emphasized that preventing metastasis remains a major challenge in treating aggressive breast cancers. Gregory pointed out that because palbociclib targets the hyperactive E2F pathway, administering it after cancer cells have spread can prevent microscopic deposits from expanding. Instead of only focusing on shrinking primary tumors, this therapeutic strategy aims to halt the progression of microscopic secondary cancers before they become life-threatening.
Peer-Reviewed Pre-Clinical Findings Published in EMBO Molecular Medicine
The research team highlighted the biological diversity of triple-negative breast cancer, which has historically complicated the development of universal targeted treatments. By identifying a specific biological vulnerability shared among a particular patient subgroup, the study paves the way for personalized therapeutic approaches. As Australian researchers continue exploring new methods to combat triple-negative breast cancer, plans are underway to validate the findings using patient-derived models ahead of clinical trials.
The results have been met with optimism by medical oncologists and cancer research organizations across Australia, who stress the urgent need for broader treatment options when primary therapies fall short. The research team intends to work with international clinical networks to accelerate biomarker screening protocols. Confirming the effectiveness of miR-342 testing could soon enable clinicians to identify suitable candidates for targeted CDK4/6 inhibitor therapies during early treatment phases.